Scientists Find APOE4 Damages Brain Vessels in a Way That Can Be Reversed
Two Mount Sinai studies reveal APOE4 actively scars brain blood vessels and drives protein buildup — and that blocking one pathway can undo the damage.
Summary
Mount Sinai researchers have identified a reversible mechanism by which APOE4, the strongest genetic risk factor for Alzheimer's disease, damages brain blood vessels. Two studies in Cell and Cell Stem Cell show that APOE4 converts pericytes — cells that stabilize tiny blood vessels — into scar-producing cells, promoting vascular fibrosis and amyloid buildup. Crucially, blocking TGF-β signaling reversed these effects in human cell models and aged mice, restoring normal vessel support and reducing harmful protein accumulation. The findings reframe vascular damage not as a symptom of Alzheimer's but as an active, treatable driver of the disease, and open new therapeutic targets for Alzheimer's, Parkinson's, and other neurodegenerative conditions.
Detailed Summary
Alzheimer's disease affects more than 7 million older adults in the United States, and carrying the APOE4 gene variant dramatically raises a person's risk. Scientists have long observed that brain blood vessels deteriorate in APOE4 carriers, but whether that damage helps cause the disease or merely accompanies it has remained unclear. Two new studies from Mount Sinai now provide a mechanistic answer — and a potential path to reversal.
The first study, published in Cell, used single-cell transcriptomic mapping to chart gene activity across all cell types in the human brain's vascular system. The researchers found that APOE4 reprograms pericytes — specialized cells that wrap around small blood vessels to stabilize them and maintain the blood-brain barrier — turning them into myofibroblast-like cells that generate scar tissue. This transformation, called vascular fibrosis, also promotes the buildup of amyloid protein around vessels, creating conditions that starve neurons of blood flow and accelerate neurodegeneration.
The second study, published in Cell Stem Cell, introduced a new human brain tissue platform derived from stem cells, designed to accelerate drug testing for neurodegenerative diseases. Together, the two papers establish that APOE4's vascular effects are not passive collateral damage but an active, biologically driven process.
Most encouragingly, the damage appears reversible. When researchers blocked TGF-β signaling — a pathway governing cell communication and tissue remodeling — pericytes recovered their normal function, fibrosis decreased, and amyloid accumulation around vessels was reduced. The result was reproduced in aged APOE4 mice, adding translational weight to the findings.
Caveats remain: mouse models do not perfectly replicate human Alzheimer's biology, and TGF-β inhibition carries broad effects that would need careful management in clinical settings. Human trials targeting this pathway are not yet underway. Nevertheless, the work reframes vascular degeneration as a targetable driver of Alzheimer's, offering a new class of therapeutic strategies for one of aging's most feared diseases.
Key Findings
- APOE4 converts pericytes into scar-producing cells, driving brain vascular fibrosis and amyloid buildup around vessels.
- Vascular damage in APOE4 carriers is an active disease driver, not just a late consequence of Alzheimer's.
- Blocking TGF-β signaling restored pericyte function and reduced fibrosis and amyloid in cell models and aged mice.
- A new stem-cell-derived human brain tissue platform was introduced to accelerate neurodegenerative drug screening.
- Findings suggest new therapeutic targets relevant to Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Methodology
This is a news report summarizing two peer-reviewed studies published in Cell and Cell Stem Cell by researchers at the Icahn School of Medicine at Mount Sinai, both high-credibility venues. Evidence includes single-cell transcriptomic atlas data, stem-cell-derived human brain tissue models, and in vivo experiments in aged APOE4 mice.
Study Limitations
Mouse models of Alzheimer's imperfectly replicate human disease progression, so reversal effects seen in aged APOE4 mice may not translate directly to patients. TGF-β is a pleiotropic signaling pathway; systemic inhibition carries risks that clinical trials would need to resolve. No human trials targeting this mechanism are currently reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: